MAR001

DRUG3 trials

Sponsors

Marea Therapeutics

Conditions

Hypertriglyceridemia

Phase 1

Study of MAR001 in Adults With Metabolic Dysfunction

CompletedNCT05896254

Marea TherapeuticsHypertriglyceridemia

Start: 2023-07-22End: 2024-12-13Updated: 2025-11-13

Phase 2

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

RecruitingNCT07028749

Marea TherapeuticsHypertriglyceridemia

Start: 2025-06-30End: 2028-04-01Target: 316Updated: 2026-09-02

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

RecruitingNCT07199309

Marea TherapeuticsHypertriglyceridemia

Start: 2025-09-26End: 2026-11-30Target: 30Updated: 2025-11-06

Related Papers

Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.

2025-05-1511 citations